Neutra Corp. (NTRR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 2851.00 USD | -96.21% |
| 2023 | 75.17 Thousand USD | -42.58% |
| 2022 | 130.93 Thousand USD | -31.37% |
| 2021 | 190.76 Thousand USD | 4.63% |
| 2020 | 182.33 Thousand USD | 11.45% |
| 2019 | 163.59 Thousand USD | 1227.35% |
| 2018 | 12.32 Thousand USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 284.00 USD | -95.69% |
| 2015 | 6584.00 USD | -85.86% |
| 2014 | 46.55 Thousand USD | 555.65% |
| 2013 | 7100.00 USD | -75.39% |
| 2012 | 28.85 Thousand USD | 188.52% |
| 2011 | 10 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 54.1 Thousand USD | -28.03% |
| 2024 FY | 2851.00 USD | -96.21% |
| 2024 Q2 | 36.94 Thousand USD | -31.72% |
| 2024 Q3 | 26.94 Thousand USD | -27.06% |
| 2024 Q4 | 2851.00 USD | -89.42% |
| 2023 Q1 | 147.32 Thousand USD | 12.52% |
| 2023 Q2 | 141.85 Thousand USD | -3.71% |
| 2023 FY | 75.17 Thousand USD | -42.58% |
| 2023 Q4 | 75.17 Thousand USD | -23.26% |
| 2023 Q3 | 97.96 Thousand USD | -30.94% |
| 2022 Q1 | 208.31 Thousand USD | 9.2% |
| 2022 Q4 | 130.93 Thousand USD | -26.71% |
| 2022 Q3 | 178.66 Thousand USD | 2.51% |
| 2022 FY | 130.93 Thousand USD | -31.37% |
| 2022 Q2 | 174.28 Thousand USD | -16.33% |
| 2021 Q2 | 185.49 Thousand USD | 38.51% |
| 2021 FY | 190.76 Thousand USD | 4.63% |
| 2021 Q3 | 166.27 Thousand USD | -10.36% |
| 2021 Q4 | 190.76 Thousand USD | 14.73% |
| 2021 Q1 | 133.91 Thousand USD | -26.55% |
| 2020 Q1 | 105.81 Thousand USD | -35.32% |
| 2020 Q3 | 15.69 Thousand USD | -76.21% |
| 2020 FY | 182.33 Thousand USD | 11.45% |
| 2020 Q4 | 182.33 Thousand USD | 1061.66% |
| 2020 Q2 | 65.96 Thousand USD | -37.66% |
| 2019 Q2 | 30.63 Thousand USD | -67.06% |
| 2019 Q3 | 110.92 Thousand USD | 262.16% |
| 2019 Q4 | 163.59 Thousand USD | 47.48% |
| 2019 FY | 163.59 Thousand USD | 1227.35% |
| 2019 Q1 | 92.97 Thousand USD | 654.39% |
| 2018 Q2 | 10.29 Thousand USD | -76.71% |
| 2018 Q3 | 22.45 Thousand USD | 118.11% |
| 2018 Q4 | 12.32 Thousand USD | -45.1% |
| 2018 FY | 12.32 Thousand USD | 0.0% |
| 2018 Q1 | 44.2 Thousand USD | 0.0% |
| 2017 Q3 | - USD | -100.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | -100.0% |
| 2017 Q1 | 9349.00 USD | 3191.9% |
| 2017 Q2 | 1181.00 USD | -87.37% |
| 2016 Q1 | 8061.00 USD | 22.43% |
| 2016 FY | 284.00 USD | -95.69% |
| 2016 Q4 | 284.00 USD | -54.19% |
| 2016 Q3 | 620.00 USD | -17.11% |
| 2016 Q2 | 748.00 USD | -90.72% |
| 2015 Q1 | 114.1 Thousand USD | 145.11% |
| 2015 Q4 | 6584.00 USD | -28.01% |
| 2015 FY | 6584.00 USD | -85.86% |
| 2015 Q3 | 9146.00 USD | -70.44% |
| 2015 Q2 | 30.94 Thousand USD | -72.88% |
| 2014 Q4 | 46.55 Thousand USD | -48.89% |
| 2014 FY | 46.55 Thousand USD | 555.65% |
| 2014 Q1 | 138.94 Thousand USD | 1856.94% |
| 2014 Q2 | 227.61 Thousand USD | 63.82% |
| 2014 Q3 | 91.08 Thousand USD | -59.98% |
| 2013 Q4 | 7100.00 USD | -6.33% |
| 2013 FY | 7100.00 USD | -75.39% |
| 2013 Q2 | 9197.00 USD | -63.12% |
| 2013 Q3 | 7580.00 USD | -17.58% |
| 2013 Q1 | 24.93 Thousand USD | -13.57% |
| 2012 Q2 | 30.04 Thousand USD | 374.32% |
| 2012 Q4 | 28.85 Thousand USD | 8.95% |
| 2012 FY | 28.85 Thousand USD | 188.52% |
| 2012 Q3 | 26.48 Thousand USD | -11.87% |
| 2012 Q1 | 6335.00 USD | 0.0% |
| 2011 FY | 10 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -23.42% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 99.854% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.973% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 99.484% |
| Rebus Holdings, Inc. | 5000.00 USD | 42.98% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.998% |
| Qrons Inc. | 420.00 USD | -578.81% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 99.63% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.99% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 99.407% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.976% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.993% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 99.961% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 96.266% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.997% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 99.801% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | 96.06% |
| Mesoblast Limited | 667.9 Million USD | 100.0% |
| Marizyme, Inc. | 22.01 Million USD | 99.987% |
| Genus plc | 1.02 Billion USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 99.79% |
| Pharming Group N.V. | 462.85 Million USD | 99.999% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 99.914% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 99.429% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 99.545% |
| ContraFect Corporation | 20.67 Million USD | 99.986% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 99.27% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 99.254% |
| IMV Inc. | 31.33 Million USD | 99.991% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 99.931% |
| MultiCell Technologies, Inc. | 126.22 USD | -2158.755% |
| ONE Bio Corp. | 70.08 Million USD | 99.996% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 99.697% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.998% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 99.34% |
| Q BioMed Inc. | 3.51 Million USD | 99.919% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.992% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 98.909% |
| Biomind Labs Inc. | 73.81 Thousand USD | 96.138% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.999% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 99.803% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.991% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 99.896% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 99.585% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 99.89% |
| GB Sciences, Inc. | 103.44 Thousand USD | 97.244% |
| Alpha Cognition Inc. | 2.45 Million USD | 99.884% |
| HST Global, Inc. | 1526.00 USD | -86.828% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 99.711% |
| Halberd Corporation | 10.13 Thousand USD | 71.859% |
| Enzolytics Inc. | 361.7 Million USD | 99.999% |
| Agentix Corp. | 261.39 Thousand USD | 98.909% |
| Resverlogix Corp. | 8.11 Million USD | 99.965% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 99.848% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.994% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 99.554% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | 87.485% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 99.968% |
| AVAX Technologies, Inc. | 7.37 Million USD | 99.961% |
| Zenith Capital Corp. | 7410.00 USD | 61.525% |
| Genscript Biotech Corporation | 3.38 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 184.00 USD | -1449.457% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 99.114% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 98.909% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 99.693% |
| Kadimastem Ltd | 2.3 Million USD | 99.876% |
| Helix BioMedix, Inc. | 3.02 Million USD | 99.906% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.995% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.98% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | 95.006% |
| LadRx Corporation | 2.3 Million USD | 99.876% |
| Cell Source, Inc. | 195.17 Thousand USD | 98.539% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 99.194% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 99.194% |
| NovAccess Global Inc. | 62.24 Thousand USD | 95.42% |
| Affymax, Inc. | 7.44 Million USD | 99.962% |
| Itoco Inc. | 1.4 Million USD | 99.796% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 97.02% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 97.31% |
| Mobile Lads Corp. | 52.00 USD | -5382.692% |
| CytoDyn Inc. | 11.13 Million USD | 99.974% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 98.006% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | 84.055% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 99.26% |
| SYBLEU INC | 330.46 Thousand USD | 99.137% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 99.304% |
| International Stem Cell Corporation | 5.39 Million USD | 99.947% |
| Bioxytran, Inc. | 137.63 Thousand USD | 97.929% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.981% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.983% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 96.391% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 99.67% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 99.962% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.991% |
| PureTech Health plc | 693.97 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 99.965% |
| IXICO plc | 15.84 Million USD | 99.982% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 99.966% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.997% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.999% |